Traws Pharma
TRAW
12 hedge funds and large institutions have $5.79M invested in Traws Pharma in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
30% less capital invested
Capital invested by funds: $8.23M → $5.79M (-$2.44M)
86% less call options, than puts
Call options by funds: $1K | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$978K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$734K |
| 3 |
D.E. Shaw & Co
New York
|
+$245K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$245K |
| 5 |
Millennium Management
New York
|
+$245K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$1.5M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.22M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$615K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$245K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$245K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIM
26
BlackRock Investment Management
Wilmington,
Delaware
| $7K | – | – | – |
|
27
Group One Trading
Chicago,
Illinois
| $6K | – | – | – |
|
28
Morgan Stanley
New York
| $6K | – | – | – |
|
29
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $4K | – | – | – |
|
30
Barclays
London,
United Kingdom
| $2K | – | – | – |
|
|
DA
31
Dunvegan Associates
Santa Barbara,
California
| $2K | – | – | – |
|
32
Simplex Trading
Chicago,
Illinois
| $2K | – | – | – |
|
|
NFG
33
Next Financial Group
Houston,
Texas
| $1K | – | – | – |
|
34
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | – | – | – |
|
|
SCM
35
Sarissa Capital Management
Greenwich,
Connecticut
| – | -$1.5M | -6 | Closed |
|
|
36
Fidelity Investments
Boston,
Massachusetts
| – | -$615K | -3 | Closed |
|
37
ProShare Advisors
Bethesda,
Maryland
| – | -$48K | – | – |
|
|
TRCT
38
Tower Research Capital (TRC)
New York
| – | -$45K | – | – |
|
|
VKH
39
Virtu KCG Holdings
New York
| – | -$48K | – | – |
|
40
Wells Fargo
San Francisco,
California
| – | -$30K | – | – |
|
TRAW Hedge Fund Activity: Q4 2014 in Review
12 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2014, worth a combined $5.79M — down 30% from $8.23M a quarter earlier.
Fund positioning in TRAW was balanced in Q4 2014: 5 funds opened new positions, 5 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Great Point Partners, adding an estimated $978K. The largest seller was Sarissa Capital Management, exiting entirely with an estimated $1.5M sold.
- 12 institutional investors held Traws Pharma (TRAW) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $5.79M of Traws Pharma stock for Q4 2014, down 30% quarter-over-quarter.
- 5 funds opened new Traws Pharma positions in Q4 2014 and 5 closed out, a net change of 0 holders.
- The largest Traws Pharma buyer in Q4 2014 was Great Point Partners, an estimated $978K added.
- The largest Traws Pharma seller in Q4 2014 was Sarissa Capital Management, an estimated $1.5M sold.
Based on aggregated 13F filings for Q4 2014.